| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2023 | 2756.46% | Chardan Capital | $14 → $12 | Maintains | Buy |
| 06/26/2023 | 1494.86% | EF Hutton | → $6.7 | Reiterates | Buy → Buy |
| 05/25/2023 | 1494.86% | EF Hutton | → $6.7 | Assumes | → Buy |
| 05/11/2023 | 3232.54% | Chardan Capital | $17 → $14 | Maintains | Buy |
| 04/19/2023 | 1494.86% | EF Hutton | → $6.7 | Reiterates | → Buy |
| 04/19/2023 | 3946.66% | Chardan Capital | $22 → $17 | Maintains | Buy |
| 02/15/2023 | 1494.86% | EF Hutton | → $6.7 | Reiterates | → Buy |
| 12/19/2022 | 1494.86% | EF Hutton | → $6.7 | Initiates Coverage On | → Buy |
| 09/22/2022 | 5136.85% | Chardan Capital | $2 → $22 | Maintains | Buy |
| 08/16/2022 | 376.08% | Chardan Capital | $2.5 → $2 | Maintains | Buy |
| 02/09/2022 | 376.08% | BTIG | $5 → $2 | Maintains | Buy |
| 12/20/2021 | 495.1% | Chardan Capital | $8 → $2.5 | Maintains | Buy |
| 12/16/2021 | 376.08% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 09/15/2021 | 1090.19% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 09/04/2020 | 1804.31% | Chardan Capital | $7 → $8 | Maintains | Buy |
| 06/05/2020 | 1566.27% | Chardan Capital | → $7 | Initiates Coverage On | → Buy |
What is the target price for Sonnet BioTherapeutics (SONN)?
The latest price target for Sonnet BioTherapeutics (NASDAQ: SONN) was reported by Chardan Capital on August 16, 2023. The analyst firm set a price target for $12.00 expecting SONN to rise to within 12 months (a possible 2756.46% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sonnet BioTherapeutics (SONN)?
The latest analyst rating for Sonnet BioTherapeutics (NASDAQ: SONN) was provided by Chardan Capital, and Sonnet BioTherapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for Sonnet BioTherapeutics (SONN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sonnet BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sonnet BioTherapeutics was filed on August 16, 2023 so you should expect the next rating to be made available sometime around August 16, 2024.
Is the Analyst Rating Sonnet BioTherapeutics (SONN) correct?
While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a maintained with a price target of $14.00 to $12.00. The current price Sonnet BioTherapeutics (SONN) is trading at is $0.42, which is out of the analyst's predicted range.